At a glance
ClinicalIndex Comparison RecordN/ACompleted· 111 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Retrospective Observational Study of Adult Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib as Extended Adjuvant Therapy in the Context of the European Early Access Program (NEAR)
In Brief
An observational study for Breast Cancer and 2 related conditions. Completed, enrolled 111 participants across 25 sites in 5 countries.
Detailed Summary
The purpose of this study is to describe the demographic and clinical profiles of patients with early-stage HER2+ breast cancer treated with neratinib as an extended adjuvant therapy as part of the Early Access Program (EAP) in Europe.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Adjuvant Therapy, HER2-positive Breast Cancer
CountriesBelgium, Croatia, France, Italy, Spain
CollaboratorsIQVIA Pty Ltd
Timeline
N/ACompletedFinished
2023202420252026
Enrollment StartJul 2022
First PostedOct 2022
Primary CompletionJan 2023
TodayJul 2026
First PostedOct 31, 2022
Enrollment StartJul 5, 2022
Primary CompletionJan 30, 2023
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 3.7 years ago